World's Best Scientists 2026 revealed!

D-Index & Metrics

Chemistry

D-Index
53
Citations
10657
World Ranking
13024
National Ranking
3439

Chao Yie Yang publication distribution in Chemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Chemistry in 2026. The highlighted bar marks where Chao Yie Yang sits on this spectrum.

61–80 publications: 66 scientists 81–100 publications: 302 scientists 101–120 publications: 623 scientists 121–140 publications: 918 scientists 141–160 publications: 1,218 scientists 161–180 publications: 1,350 scientists 181–200 publications: 1,344 scientists 201–220 publications: 1,281 scientists 221–240 publications: 1,216 scientists 241–260 publications: 1,100 scientists 261–280 publications: 979 scientists 281–300 publications: 939 scientists 301–320 publications: 764 scientists 321–340 publications: 643 scientists 341–360 publications: 628 scientists 361–380 publications: 522 scientists 381–400 publications: 459 scientists 401–420 publications: 397 scientists 421–440 publications: 327 scientists 441–460 publications: 270 scientists 461–480 publications: 265 scientists 481–500 publications: 252 scientists 501–520 publications: 201 scientists 521–540 publications: 185 scientists 541–560 publications: 148 scientists 561–580 publications: 148 scientists 581–600 publications: 132 scientists 601–620 publications: 114 scientists 621–640 publications: 104 scientists 641–660 publications: 91 scientists 661–680 publications: 92 scientists 681–700 publications: 73 scientists 701–720 publications: 57 scientists 721–740 publications: 54 scientists 741–760 publications: 67 scientists 761–780 publications: 45 scientists 781–800 publications: 46 scientists 801–820 publications: 39 scientists 821–840 publications: 32 scientists 841–860 publications: 36 scientists 861–880 publications: 29 scientists 881–900 publications: 26 scientists 901–920 publications: 24 scientists 921–940 publications: 14 scientists 941–960 publications: 23 scientists 961–980 publications: 28 scientists 981–1,000 publications: 15 scientists 1,001–1,020 publications: 29 scientists 1,021–1,040 publications: 12 scientists 1,041–1,060 publications: 19 scientists 1,061–1,080 publications: 12 scientists 1,081–1,100 publications: 6 scientists 1,101–1,120 publications: 8 scientists 1,121–1,140 publications: 12 scientists 1,141–1,160 publications: 5 scientists 1,161–1,180 publications: 6 scientists 1,181–1,200 publications: 14 scientists 1,201–1,220 publications: 7 scientists 1,221–1,240 publications: 2 scientists 1,241–1,260 publications: 6 scientists 1,261–1,280 publications: 4 scientists 1,281–1,294 publications: 6 scientists 1,295+ publications: 100 scientists
61 publications 1,295+

This scientist: 117 publications — 5th percentile

5% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,295 publications or more.

Chao Yie Yang D-index placement in Chemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Chemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Chao Yie Yang sits on this spectrum.

40–41 D-Index: 289 scientists 42–43 D-Index: 612 scientists 44–45 D-Index: 808 scientists 46–47 D-Index: 776 scientists 48–49 D-Index: 835 scientists 50–51 D-Index: 861 scientists 52–53 D-Index: 872 scientists 54–55 D-Index: 933 scientists 56–57 D-Index: 1,051 scientists 58–59 D-Index: 930 scientists 60–61 D-Index: 882 scientists 62–63 D-Index: 834 scientists 64–65 D-Index: 731 scientists 66–67 D-Index: 775 scientists 68–69 D-Index: 683 scientists 70–71 D-Index: 646 scientists 72–73 D-Index: 561 scientists 74–75 D-Index: 501 scientists 76–77 D-Index: 437 scientists 78–79 D-Index: 388 scientists 80–81 D-Index: 354 scientists 82–83 D-Index: 292 scientists 84–85 D-Index: 275 scientists 86–87 D-Index: 254 scientists 88–89 D-Index: 235 scientists 90–91 D-Index: 185 scientists 92–93 D-Index: 192 scientists 94–95 D-Index: 155 scientists 96–97 D-Index: 163 scientists 98–99 D-Index: 125 scientists 100–101 D-Index: 105 scientists 102–103 D-Index: 105 scientists 104–105 D-Index: 112 scientists 106–107 D-Index: 88 scientists 108–109 D-Index: 68 scientists 110–111 D-Index: 69 scientists 112–113 D-Index: 65 scientists 114–115 D-Index: 79 scientists 116–117 D-Index: 61 scientists 118–119 D-Index: 44 scientists 120–121 D-Index: 37 scientists 122–123 D-Index: 40 scientists 124–125 D-Index: 33 scientists 126–127 D-Index: 26 scientists 128–129 D-Index: 34 scientists 130–131 D-Index: 35 scientists 132–133 D-Index: 25 scientists 134–135 D-Index: 27 scientists 136–137 D-Index: 17 scientists 138–139 D-Index: 16 scientists 140–141 D-Index: 20 scientists 142–143 D-Index: 20 scientists 144–145 D-Index: 15 scientists 146–147 D-Index: 9 scientists 148–149 D-Index: 9 scientists 150–151 D-Index: 16 scientists 152–153 D-Index: 11 scientists 154–155 D-Index: 9 scientists 156–157 D-Index: 3 scientists 158 D-Index: 3 scientists 159+ D-Index: 98 scientists
40 D-Index 159+

This scientist: 53 D-Index — 28th percentile

28% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 159 D-Index or more.

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Enzyme
  • Biochemistry

Chao Yie Yang mostly deals with Biochemistry, Apoptosis, Cell biology, XIAP and Cancer research. His study focuses on the intersection of Apoptosis and fields such as Cell culture with connections in the field of Cell growth, Small molecule, Leukemia, STAT3 and Myeloid leukemia. His research integrates issues of Caspase, Activator and DNA-binding protein in his study of Cell biology.

As part of the same scientific family, Chao Yie Yang usually focuses on XIAP, concentrating on Inhibitor of apoptosis and intersecting with Pharmacology, Orally active, Bioavailability, Antagonist and Cancer cell. His Cancer research research is multidisciplinary, incorporating elements of Clinical trial, Mdm2, Mdm2 p53, Function and STAT protein. His research in Structure–activity relationship intersects with topics in Combinatorial chemistry, Smac mimetics, Protein structure and Stereochemistry.

His most cited work include:

  • The PDBbind database: methodologies and updates. (407 citations)
  • Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. (246 citations)
  • A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment (185 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Cancer research, Small molecule, Biochemistry, Cell growth and Apoptosis. His work carried out in the field of Cancer research brings together such families of science as Proteolysis targeting chimera, Cancer, Molecular biology, Androgen receptor and In vivo. His study in Small molecule is interdisciplinary in nature, drawing from both Ligand binding assay, Biophysics, Stereochemistry, Peptidomimetic and Binding site.

He has included themes like Cell culture, Bromodomain, BRD4, Programmed cell death and Structure–activity relationship in his Cell growth study. His Apoptosis research incorporates elements of Cancer cell, In vitro, Cytotoxicity and Cell biology. His XIAP study integrates concerns from other disciplines, such as Inhibitor of apoptosis, Smac mimetics, Combinatorial chemistry and Bivalent.

He most often published in these fields:

  • Cancer research (28.33%)
  • Small molecule (26.67%)
  • Biochemistry (26.67%)

What were the highlights of his more recent work (between 2018-2021)?

  • Cancer research (28.33%)
  • Cell growth (24.17%)
  • Cancer (10.83%)

In recent papers he was focusing on the following fields of study:

His main research concerns Cancer research, Cell growth, Cancer, Proteolysis targeting chimera and Cell culture. His Cell growth research is multidisciplinary, relying on both Mutation, IC50 and Oral administration, Pharmacology. The study incorporates disciplines such as Receptor, Protein degradation and Proteolysis in addition to Proteolysis targeting chimera.

The research on Cell biology and Biochemistry is part of his Protein degradation project. Chao Yie Yang combines subjects such as EZH2, Myeloid leukemia, Small molecule, Structure–activity relationship and In vivo with his study of Cell culture. The Myeloid leukemia study combines topics in areas such as Cancer cell, Apoptosis, Leukemia and Kinase.

Between 2018 and 2021, his most popular works were:

  • A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo (91 citations)
  • Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. (88 citations)
  • Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression. (81 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Enzyme
  • Cancer

His scientific interests lie mostly in Cancer research, Proteolysis targeting chimera, Cell growth, Protein degradation and Proteolysis. His studies in Cancer research integrate themes in fields like Cell culture and STAT3, STAT protein. His research on Cell culture frequently connects to adjacent areas such as In vivo.

To a larger extent, he studies Apoptosis with the aim of understanding STAT3. His Cell growth research integrates issues from Ubiquitin ligase, Receptor and Androgen receptor, LNCaP, Prostate cancer. His Protein degradation study is focused on Biochemistry in general.

Best Publications

  • The PDBbind database: methodologies and updates.

    Renxiao Wang;Xueliang Fang;Yipin Lu;Chao Yie Yang

  • A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

    Longchuan Bai;Haibin Zhou;Renqi Xu;Yujun Zhao

  • Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.

    Guoping Wang;Zaneta Nikolovska-Coleska;Chao Yie Yang;Renxiao Wang

  • Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.

    Xin Han;Chao Wang;Chong Qin;Weiguo Xiang

  • Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression

    Bing Zhou;Jiantao Hu;Fuming Xu;Zhuo Chen

  • Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.

    Yangbing Li;Jiuling Yang;Angelo Aguilar;Donna McEachern

  • Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression

    Chong Qin;Yang Hu;Bing Zhou;Ester Fernandez-Salas

  • A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment

    Qian Cai;Haiying Sun;Yuefeng Peng;Yuefeng Peng;Jianfeng Lu

  • Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP.

    Haiying Sun;Zaneta Nikolovska-Coleska;Jianfeng Lu;Jennifer L. Meagher

  • Design of Triazole-Stapled BCL9 α-Helical Peptides to Target the β-Catenin/B-Cell CLL/lymphoma 9 (BCL9) Protein–Protein Interaction

    Steven A. Kawamoto;Adriana Coleska;Xu Ran;Han Yi

  • Design of Small-Molecule Peptidic and Nonpeptidic Smac Mimetics

    Haiying Sun;Zaneta Nikolovska-Coleska;Chao Yie Yang;Dongguang Qian

  • Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).

    Jiantao Hu;Biao Hu;Mingliang Wang;Fuming Xu

  • Analysis of ligand-bound water molecules in high-resolution crystal structures of protein-ligand complexes.

    Yipin Lu;Renxiao Wang;Chao Yie Yang;Shaomeng Wang

  • Structure-based design of potent, conformationally constrained Smac mimetics

    Haiying Sun;Zaneta Nikolovska-Coleska;Chao Yie Yang;Liang Xu

  • Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.

    Xin Han;Lijie Zhao;Weiguo Xiang;Chong Qin

  • Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.

    Xinrui Yuan;Xinrui Yuan;Hong Bu;Jinpei Zhou;Chao-Yie Yang

  • Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.

    Haibin Zhou;Longchuan Bai;Renqi Xu;Yujun Zhao

  • The FHA and BRCT domains recognize ADP-ribosylation during DNA damage response.

    Mo Li;Lin Yu Lu;Chao Yie Yang;Shaomeng Wang

  • Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site.

    Haiying Sun;Zaneta Nikolovska-Coleska;Chao Yie Yang;Liang Xu

  • Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.

    Jiuling Yang;Yangbing Li;Angelo Aguilar;Zhaomin Liu

  • CSAR Benchmark Exercise of 2010: Selection of the Protein–Ligand Complexes

    James B. Dunbar;Richard D. Smith;Chao Yie Yang;Peter Man Un Ung

Frequent Co-Authors

Shaomeng Wang
Shaomeng Wang University of Michigan–Ann Arbor
Jeanne A. Stuckey
Jeanne A. Stuckey University of Michigan–Ann Arbor
Duxin Sun
Duxin Sun University of Michigan–Ann Arbor
Peter P. Roller
Peter P. Roller National Institutes of Health
Ke Ding
Ke Ding Jinan University
Sophie Paczesny
Sophie Paczesny Medical University of South Carolina
Yi Sun
Yi Sun Zhejiang University
Richard D. Smith
Richard D. Smith Pacific Northwest National Laboratory
Heather A. Carlson
Heather A. Carlson University of Michigan–Ann Arbor
Daniel F. Hayes
Daniel F. Hayes University of Michigan–Ann Arbor

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Chemistry in the USA opens doors to various online degree options and diverse career pathways. For those exploring flexible learning formats, understanding the criminal justice degree price is essential, as it highlights how affordable and accessible online programs can be across disciplines, including science-adjacent fields.

Students seeking foundational qualifications might consider programs like the online associates in criminal justice, which provide solid career entry points with flexible schedules. While not directly linked to Chemistry, these programs share the advantage of remote learning and practical skill development that can complement scientific expertise.

Additionally, pursuing specialized fields through various paralegal degree programs can broaden one's career options, particularly in regulatory or patent law related to chemical innovations. Understanding these degrees and their potential salaries aids in making informed career decisions.

For Chemistry graduates interested in industry roles, becoming a pharmaceutical sales representative is a promising pathway. Learning how much do drug reps make and the steps required to enter this field provides valuable insight into combining scientific knowledge with sales and marketing skills.

Best Scientists Citing Chao Yie Yang

Trending Scientists

Recently Published Articles